Taken together, our study provides evidence that a synthetic dsP53-285 holds potent ability to activate wild-type p53 expression by targeting complementary motifs in promoter region of human bladder cancer T24 and EJ cells. This evidence concerns the gene TP53 and urinary bladder cancer.